CG Oncology (CGON) CEO receives 271,600 stock options at $67.68 strike

Rhea-AI Filing Summary

CG Oncology, Inc. reported that Chief Executive Officer Arthur Kuan received a grant of employee stock options covering 271,600 shares of common stock. The options have an exercise price of $67.68 per share and expire on April 14, 2036.

According to the award terms, 1/48th of the shares subject to the option vest monthly following April 15, 2026, as long as Kuan continues to provide services to the company through each vesting date. After this grant, he holds 271,600 derivative securities linked to common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kuan Arthur

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	271,600	$0.00	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 271,600 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Option shares granted: 271,600 options Exercise price: $67.68 per share Expiration date: April 14, 2036 +2 more

5 metrics

Option shares granted 271,600 options Employee stock option grant to CEO on April 15, 2026

Exercise price $67.68 per share Strike price for employee stock options

Expiration date April 14, 2036 Option term endpoint if unexercised

Vesting schedule 1/48 monthly Monthly vesting following April 15, 2026, subject to service

Derivative holdings after grant 271,600 derivative securities Total options held following this transaction

Key Terms

Employee Stock Option, exercise price, vesting, derivative securities, +1 more

5 terms

Employee Stock Option financial

"Employee Stock Option (Right to Buy)"

An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.

exercise price financial

"conversion_or_exercise_price": "67.6800""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"1/48th of the shares subject to the option vest monthly"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

derivative securities financial

"derivativeTransactionCount": 1"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

expiration date financial

"expiration_date": "2036-04-14T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kuan Arthur

(Last) (First) (Middle)

C/O CG ONCOLOGY, INC.

3000 PEGASUS PARK DRIVE, SUITE 1640

(Street)

DALLAS TEXAS 75247

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CG Oncology, Inc. [ CGON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$67.68	04/15/2026		A		271,600		(1)	04/14/2036	Common Stock	271,600	$0	271,600	D

Explanation of Responses:

1. 1/48th of the shares subject to the option vest monthly following April 15, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

	/s/ Joshua F. Patterson, Attorney-in-Fact for Arthur Kuan	04/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CGON CEO Arthur Kuan report on this Form 4?

Arthur Kuan reported receiving an employee stock option grant for 271,600 shares of CG Oncology common stock. The options are a compensation-related award, not an open-market purchase or sale, and give him the right to buy shares at a fixed exercise price if they vest.

What is the exercise price of the CGON stock options granted to the CEO?

The granted options have an exercise price of $67.68 per share. This means Kuan can buy CG Oncology common stock at $67.68 if he exercises the options after they vest, regardless of the market price at that future time.

How many CGON shares are covered by the new stock option grant to the CEO?

The stock option grant covers 271,600 underlying shares of CG Oncology common stock. These are derivative securities that may convert into common shares if Kuan chooses to exercise them once vested and pays the $67.68 per-share exercise price.

When do Arthur Kuan’s CGON stock options start vesting and on what schedule?

Vesting begins after April 15, 2026, the vesting commencement date. One forty-eighth of the optioned shares vests each month, so the grant vests gradually over four years, contingent on Kuan’s continuous service to CG Oncology through each monthly vesting date.

When do the CGON stock options granted to the CEO expire if unexercised?

The options expire on April 14, 2036, if not exercised. After that expiration date, Kuan would no longer have the right to purchase CG Oncology common stock under this particular employee stock option grant, even if some portions had vested.